arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Phio Pharmaceuticals Corp.

PHIO
$1.06 ▼ -0.01 (-1.40%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Phio Pharmaceuticals Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.3M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -36.2%
FCF / Share $-1.34
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-8.70M
↓ -21.7%
FCF / Share Free cash flow per share
$-1.34
↑ +85.2%
Long-Term Debt Long-term obligations
$231.00K
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 23 years · 93 quarters